1,316.43 million, up from the same period of the previous year by Baht 473.27 million mainly due to increased share of profit from associated companies as Bangkok Expressway and Metro Public Company Limited

LIMITED BDMS: BANGKOK DUSIT MEDICAL SERVICES PUBLIC COMPANY LIMITED BEM: BANGKOK EXPRESSWAY AND METRO PUBLIC COMPANY LIMITED BKD: BANGKOK DEC-CON PUBLIC COMPANY LIMITED BKGI: Bangkok Genomics Innovation

8, 2023 198.51 23/08/2022 31/08/2022 31/08/2022     BANGKOK EXPRESSWAY AND METRO PUBLIC COMPANY LIMITED Debenture - Long Term II/HNW SUSTAINABILITY DEBENTURES OF BANGKOK EXPRESSWAY AND METRO PUBLIC

had share of profit from investments in associated companies of Baht 1,657.63 million in 2018, up by Baht 834.70million, or 101.43%, from last year. The increase was mainly from Bangkok Expressway and

mainly due to the additional investment in Bangkok Expressway and Metro Public Company Limited and the investment in fixed assets. Total liabilities amounted to Baht 57,983.99 million, increasing by Baht

increase was mainly from Bangkok Expressway and Metro Public Company Limited (BEM)’s gain on fair value adjustment of investment due to reclassification in the amount of Baht 2,030 Million, net of corporate

BDMS: BANGKOK DUSIT MEDICAL SERVICES PUBLIC COMPANY LIMITED BEM: BANGKOK EXPRESSWAY AND METRO PUBLIC COMPANY LIMITED BKD: BANGKOK DEC-CON PUBLIC COMPANY LIMITED BKGI: Bangkok Genomics Innovation Public

-2 Ranking BEM BANGKOK EXPRESSWAY AND METRO PUBLIC COMPANY LIMITED Filing FinancialStatement 56-1 56-2 Ranking BKGI Bangkok Genomics Innovation Public Company Limited Filing FinancialStatement 56-1 56

server computers to support information systems of the Social Security Office, the Project of procurement and sale of network equipment connecting the Expressway Control Center building and installation of

the increase of the Company’s investment in Bangkok Expressway and Metro plc and their improved performance. Finance cost for 1H/2017 amounted to Baht 713.33 million, a rise by Baht 348.38 million or